Stockscreener 앱 받기
14.92
3.37%
-0.52
시간 외 거래:
14.92
Eyepoint Inc 주식(EYPT)의 최신 뉴스
H.C. Wainwright raises EyePoint stock price target to $30 on DME trial progress - Investing.com Nigeria
Aug Breakouts: Can EyePoint Pharmaceuticals Inc expand its profit margins2026 Intraday Action & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Chardan raises EyePoint stock price target to $29 on cash position - Investing.com Nigeria
EyePoint Pharmaceuticals Experiences Evaluation Revision Amidst Market Dynamics and Performance Fluctuations - Markets Mojo
EyePoint (EYPT) Sees Target Price Raise by Citigroup to $35 | EY - GuruFocus
EyePoint stock rating maintained at Outperform by Mizuho - Investing.com
EyePoint Reports Fourth-Quarter and Full-Year 2025 Financial Results, Provides Corporate Update - VisionMonday.com
(EYPT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Eyepoint Pharmaceuticals, Inc. $EYPT Holdings Trimmed by Blue Owl Capital Holdings LP - MarketBeat
EyePoint (EYPT) Q4 2025 Earnings Call Transcript - AOL.com
Decoding EyePoint Inc (EYPT): A Strategic SWOT Insight - GuruFocus
Is It Too Late To Consider EyePoint (EYPT) After Its 173% One Year Surge? - Yahoo Finance
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target Raised to $30.00 - MarketBeat
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2025 Earnings Call Transcript - Insider Monkey
Chardan Raises Price Target on EyePoint Pharmaceuticals to $29 From $27, Keeps Buy Rating - marketscreener.com
EyePoint (EYPT) Analyst Rating Update: Price Target Increased to $30 | EYPT Stock News - GuruFocus
EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check (NASDAQ:EYPT) - Seeking Alpha
Earnings Summary: EyePoint (EYPT) Q4 2025 net loss widens - AlphaStreet
Is It Too Late To Consider EyePoint (EYPT) After A 1‑Year Surge And DCF Upside? - simplywall.st
EyePoint Q4 2025 Financial Results: Net Loss of $67.6MNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
EyePoint: Fourth Quarter Financial Results Overview - Bitget
EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising Clinical Advances - GuruFocus
Chardan raises EyePoint stock price target to $29 on cash position By Investing.com - Investing.com South Africa
EYPT (EyePoint) Equity-to-Asset : 0.80 (As of Sep. 2025) - GuruFocus
EYPT (EyePoint) ROE % : -107.10% (As of Sep. 2025) - GuruFocus
Chardan Capital Issues Positive Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price - MarketBeat
Chardan Capital Raises Price Target for EYPT to $29.00, Maintains Buy Rating | EYPT Stock News - GuruFocus
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 4.7%Should You Sell? - MarketBeat
Earnings call transcript: Eyepoint Pharmaceuticals Q4 2025 reveals revenue drop - Investing.com Nigeria
EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Eyepoint Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
EYPT: DURAVYU's pivotal Phase III trials progress with strong safety, efficacy, and funding into 2027 - TradingView
EYPT: DURAVYU advanced in pivotal trials with strong cash reserves and key data readouts ahead - TradingView
EyePoint Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eyepoint Pharma earnings missed by $0.06, revenue fell short of estimates - Investing.com Canada
EyePoint, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
EyePoint Inc (NASDAQ:EYPT) Stock Falls on Q4 Earnings and Revenue Miss - ChartMill
EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
EyePoint Pharmaceuticals' Q4 Net Loss Widens, Revenue Drops - marketscreener.com
Earnings Flash (EYPT) EyePoint Posts Q4 Net Loss $0.81 a Share, vs. FactSet Est of $0.77 Loss - marketscreener.com
Earnings Flash (EYPT) EyePoint, Inc. Reports Q4 Revenue $620,000, vs. FactSet Est of $990,000 - marketscreener.com
EYPT Forecasts Financial Stability Through Key Program Milestones - GuruFocus
EYEPOINT PHARMACEUTICALS ($EYPT) Releases Q4 2025 Earnings - Quiver Quantitative
EyePoint: Q4 Earnings Snapshot - marketscreener.com
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments - TradingView
EyePoint Pharmaceuticals Q4 revenue plunges, net loss widens - TradingView
EYPT: DURAVYU Phase 3 trials progress, with strong cash reserves funding operations into Q4 2027 - TradingView
EyePoint (Nasdaq: EYPT) deepens 2025 loss while pushing DURAVYU into Phase 3 - Stock Titan
Earnings Summary: EyePoint Q4 - Benzinga
EyePoint at TD Cowen Conference: DURAVYU’s Market Potential By Investing.com - Investing.com Canada
EYPT: Phase 3 trials advance with unique IL-6 mechanism, targeting a $15B global retina market - TradingView
A Preview Of EyePoint Pharmaceuticals's Earnings - Benzinga
EyePoint Pharmaceuticals to Announce Q4 Earnings on March 4 - Intellectia AI
Eyepoint Pharma earnings up next as pivotal trial data looms By Investing.com - Investing.com Canada
Eyepoint Pharma earnings up next as pivotal trial data looms - Investing.com Nigeria
1.57%
0.40%
자본화:
|
볼륨(24시간):